Catalog No.: PC-24744Not For Human Use, Lab Use Only.
Cyclovirobuxine D (CVB-D) is a naturally alkaloid, induces autophagy and attenuates the phosphorylation of Akt and mTOR, exerts its anti-cancer effects by directly binding to YAP, inhibits the nuclear translocation of YAP/TAZ and suppresses the transcription of downstream oncogenic target genes.
Cyclovirobuxine D (CVB-D) is a naturally alkaloid, induces autophagy and attenuates the phosphorylation of Akt and mTOR, exerts its anti-cancer effects by directly binding to YAP, inhibits the nuclear translocation of YAP/TAZ and suppresses the transcription of downstream oncogenic target genes. Cyclovirobuxine D (CVB-D) could improve cardiac dysfunction in a cecal ligation and puncture (CLP) model in rodents and in a lipopolysaccharide (LPS) model in vitro. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. also is an inhibitor of cytoplasmic leukemia inhibitory factor (LIF) in HCC, suppresses proliferation and metastasis by activating p38MAPK/p62-modulated mitophagy. Cyclovirobuxine D inhibits triple-negative breast cancer via YAP/TAZ suppression and activation of the FOXO3a/PINK1-Parkin pathway-induced mitophagy. Cyclovirobuxine D triggers autophagy to suppress the proliferation of TNBC and promote TNBC apoptosis. Cyclovirobuxine D exhibits notable antitumor activity against diverse tumor types.
